Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
IL2-CD25 by Bristol-Myers Squibb for Systemic Lupus Erythematosus: Likelihood of Approval
IL2-CD25 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData,...
IL2-CD25 by Bristol-Myers Squibb for Subacute Cutaneous Lupus Erythematosus (SCLE): Likelihood of Approval
IL2-CD25 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Subacute Cutaneous Lupus Erythematosus (SCLE). According...
IL2-CD25 by Bristol-Myers Squibb for Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE): Likelihood of Approval
IL2-CD25 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Chronic Cutaneous Lupus Erythematosus (CCLE) /...
IL2-CD25 by Bristol-Myers Squibb for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
IL2-CD25 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Atopic Dermatitis (Atopic Eczema). According to...